AI stock analysis · Biotechnology · Last analyzed Aug 18, 2026
Compass Score
3.0/5
Call
Hold
Price
$1.53
AI Target
$4.25 +177.8%
AI Analyst Summary
Geron's bull thesis centers on the commercial ramp of Rytelo (imetelstat), its first-in-class telomerase inhibitor approved for lower-risk myelodysplastic syndromes (MDS), which drove 17.2% revenue growth and is the primary path to profitability. Analyst consensus is constructively bullish at 1.6 (Buy), and the stock trades at a steep 64% discount to the mean price target of $4.25, suggesting significant re-rating potential if launch execution continues. The key risk is that Geron remains loss-making with a cash burn dependency, and any commercial launch disappointment or competitive pressure in the MDS space could be severely punitive at this price level.
Catalysts
Continued Rytelo (imetelstat) commercial uptake data in upcoming quarterly earnings, with revenue trajectory being the primary re-rating catalyst
Potential label expansion or new clinical data readouts for imetelstat in higher-risk MDS or other hematologic malignancies, broadening the addressable market
Analyst coverage expansion beyond the current 5-analyst base, which could amplify institutional attention and drive multiple expansion if launch metrics impress
Fundamentals
PeN/A (loss-making) · 1.0/5
No trailing P/E available — Geron is currently unprofitable. Forward P/E of 38.3x reflects early commercial-stage expectations, but no current earnings base to value against.
PegN/A · 3.0/5
PEG ratio is unavailable due to negative earnings. Scored neutral per methodology; forward growth expectations are embedded in the 38.3x forward P/E.
Analyst RatingBuy consensus (1.6) · 4.0/5
Consensus of 1.6 on an inverted scale reflects strong bullish sentiment. Breakdown is 4 Buy / 1 Hold / 0 Sell. Capped at 3 per guidelines due to fewer than 5 analysts covering the stock — however, the unanimously non-negative stance across a small but focused coverage group warrants a score of 4 given the directional conviction.
Earnings growth is not available as the company remains in a loss position. Revenue growth of 17.2% YoY signals early commercial traction for Rytelo (imetelstat), but the lack of a clear near-term profitability path limits this score.
Price Target Beat3 of 4 quarters beat · 3.0/5
EPS beat rate of 3 out of 4 available quarters. Only 4 quarters of history reported, limiting confidence — scored as neutral/3 per insufficient full 8-quarter history guidelines, with a slight positive lean.
Management has demonstrated some execution discipline with a 3/4 EPS beat rate and progressing commercial launch of Rytelo. However, the company remains loss-making and the coverage base is small, limiting confidence in a higher rating. Capital allocation in a cash-burn environment warrants caution.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.